Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C.

Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A.

World J Hepatol. 2017 Mar 8;9(7):352-367. doi: 10.4254/wjh.v9.i7.352. Review.

2.

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.

Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S.

World J Hepatol. 2017 Feb 18;9(5):252-262. doi: 10.4254/wjh.v9.i5.252.

3.

Extrahepatic manifestations in hepatitis C virus infection.

Negro F, Esmat G.

J Adv Res. 2017 Mar;8(2):85-87. doi: 10.1016/j.jare.2016.08.004. Epub 2016 Aug 25. No abstract available.

4.
5.

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C.

PLoS One. 2017 Jan 3;12(1):e0169401. doi: 10.1371/journal.pone.0169401. eCollection 2017 Jan 3.

6.

Assessment of 4 Cases of Kidney Transplantation from Hepatitis C Virus Antibody-Positive and RNA-Negative Donors to Antibody-Negative Recipients.

Unagami K, Ishida H, Okumi M, Hirai T, Toki D, Omoto K, Shimizu T, Inui M, Nitta K, Tanabe K.

Transplant Direct. 2016 Aug 26;2(9):e102. eCollection 2016 Aug 26. No abstract available.

7.

Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic.

Mendes LC, Ralla SM, Vigani AG.

Braz J Med Biol Res. 2016 Aug 25;49(10):e5455. doi: 10.1590/1414-431X20165455.

8.

Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients.

Noritake H, Kobayashi Y, Ooba Y, Kitsugi K, Shimoyama S, Yamazaki S, Chida T, Watanabe S, Kawata K, Suda T.

ISRN Hepatol. 2014 Feb 4;2014:875140. doi: 10.1155/2014/875140. eCollection 2014 Feb 4.

9.

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M.

PLoS One. 2016 Jun 15;11(6):e0155967. doi: 10.1371/journal.pone.0155967. eCollection 2016 Jun 15.

10.

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Al-Mahtab M, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK.

Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.

11.

Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease.

Maan R, van der Meer AJ.

F1000Res. 2016 Mar 17;5. pii: F1000 Faculty Rev-367. doi: 10.12688/f1000research.7399.1. eCollection 2016 Mar 17. Review.

12.

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.

Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, Lovell S, Ng TI, Liu W, Campbell A, Lin CW, Yao B, Kort J.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1546-55. doi: 10.1128/AAC.02264-15.

13.

Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.

Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H.

World J Hepatol. 2015 Nov 28;7(27):2757-64. doi: 10.4254/wjh.v7.i27.2757.

14.

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.

Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG.

JAMA Intern Med. 2016 Jan;176(1):65-73. doi: 10.1001/jamainternmed.2015.6011.

15.

Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.

Vargas CL, Espinoza MA, Giglio A, Soza A.

PLoS One. 2015 Nov 6;10(11):e0141660. doi: 10.1371/journal.pone.0141660. eCollection 2015 Nov 6.

16.

Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.

Maan R, de Knegt RJ, Veldt BJ.

Drugs. 2015 Nov;75(17):1981-92. doi: 10.1007/s40265-015-0480-0. Review.

17.

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.

Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B, Librant-Suska M, Lojewski W, Jurczyk K, Musialik J, Postawa-Klosińska B, Wroblewski J, Augustyniak K, Dudziak M, Olszok I, Ruszala A, Pisula A, Lapinski T, Kryczka W, Horban A, Dobracki W.

Medicine (Baltimore). 2015 Sep;94(38):e1411. doi: 10.1097/MD.0000000000001411.

18.

Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C.

Noritake H, Kobayashi Y, Ooba Y, Matsunaga E, Ohta K, Shimoyama S, Yamazaki S, Chida T, Kawata K, Sakaguchi T, Suda T.

J Interferon Cytokine Res. 2015 Dec;35(12):956-62. doi: 10.1089/jir.2014.0197. Epub 2015 Aug 26.

19.

Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy.

D'Ambrosio R, Della Corte C, Colombo M.

Int J Mol Sci. 2015 Aug 19;16(8):19698-712. doi: 10.3390/ijms160819698. Review.

20.

Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.

Gissel C, Götz G, Mahlich J, Repp H.

BMC Infect Dis. 2015 Jul 30;15:297. doi: 10.1186/s12879-015-1048-z.

Supplemental Content

Support Center